The Monday Brief — Week of Jul 12, 2026

Steel Partners, an InMode shareholder, has tabled an unsolicited $16.75-per-share cash offer to acquire the company, topping a CEO-led buyout bid. The move signals confidence in InMode's Pulse 2.0 platform and broader device portfolio—and reflects investor appetite for consolidation in the aesthetic-tech space. Owners using InMode systems should monitor this closely: acquisition outcomes often trigger pricing shifts, support changes, and product roadmap adjustments. The competing bids may drag out, creating uncertainty around service, upgrades, and financing terms. Watch for updates on which offer prevails and what it means for your existing relationships and contracts.

AbbVie (Allergan Aesthetics) and Evolus both filed material events this week signaling pricing and loyalty program changes. AbbVie's Botox/Juvéderm + Allē loyalty moves and Evolus's aggressive Jeuveau/Newtox + Evolus Rewards strategy are classic bellwether signals: expect rebate restructuring, volume incentives, and tiered pricing to ripple across the market. These aren't minor tweaks—they're designed to lock in volume and shift margins. Review your current contracts, rebate structures, and loyalty commitments now. Smaller practices often absorb margin compression first; larger groups negotiate harder. Don't wait for your rep to call.

Medicare will negotiate the price of Botox and 14 other drugs this year, adding regulatory pressure to an already competitive market. Meanwhile, Galderma's RelabotulinumtoxinA is progressing through FDA review, and Teijin's XEOMIN is expanding indications in Japan—signaling a crowded toxin pipeline. L'Oréal's 20% stake in Galderma underscores the strategic value of the category. For owners: toxin pricing is under siege from multiple angles. Diversify your injectable portfolio, lock in favorable terms before Medicare negotiations finalize, and prepare for new competitor entry. The toxin monopoly is ending.

Post-weight-loss body contouring is surging as GLP-1 adoption accelerates, driving demand for fractional RF, laser, and microneedle platforms. The fractional RF body device market alone is projected at $2.3 billion, with Cynosure Lutronic's XERF™ gaining rapid North American adoption. SkinStylus® just received new FDA clearance for periorbital wrinkles. This is a high-margin, high-volume opportunity—but it requires capital investment and staff training. If you haven't positioned your practice for body contouring, now is the time. Owners with RF and laser capacity are capturing this wave; those without are losing revenue.

Evolus secured exclusive U.S. distribution rights for Profhilo from IBSA under a 15-year licensing deal with no upfront fees. This skin-quality injectable expands Evolus's portfolio beyond toxins and fillers, signaling a shift toward multi-modality injectables. Profhilo is established in Europe and Asia as a hydration and collagen-stimulation play—a different category from traditional fillers. Owners should expect aggressive U.S. launch marketing and potential margin pressure as Evolus competes for shelf space and patient preference. Monitor pricing, rebates, and clinical data as the rollout unfolds.

The FDA issued warnings to websites illegally marketing Botox and related products, underscoring regulatory scrutiny of unlicensed distribution. Meanwhile, the botulinum toxin market is projected to hit $23.34 billion by 2035, driven by Millennial adoption nearly matching Gen X—a demographic shift that favors preventive, lower-dose treatments and subscription models. The market is growing, but it's also under regulatory and competitive pressure. Ensure your practice is sourcing from licensed distributors, maintaining proper documentation, and educating patients on the risks of black-market toxins. Compliance is competitive advantage.